Role of Somatodendritic 5-HT Autoreceptors in Modulating 5-HT Neurotransmission

A very important element controlling serotonin (5-HT) release throughout the brain is the 5-HT1A autoreceptor present on the soma and dendrites of 5-HT neurons since it exerts a negative feedback influence on their firing activity. This 5-HT1A autoreceptor receives an increased activation by endogen...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 1998-12, Vol.861 (1), p.204-216
Main Authors: BLIER, P., PIÑEYRO, G., EL MANSARI, M., BERGERON, R., DE MONTIGNY, C.
Format: Article
Language:English
Subjects:
8-Hydroxy-2-(di-n-propylamino)tetralin - metabolism
8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology
Animals
Brain - physiology
Dendrites - physiology
Feedback
Neurons - drug effects
Neurons - physiology
Pindolol - pharmacology
Pyrimidines - pharmacology
Receptors, Serotonin - drug effects
Receptors, Serotonin - physiology
Serotonin - physiology
Serotonin Antagonists - pharmacology
Serotonin Receptor Agonists - pharmacology
Serotonin Uptake Inhibitors - pharmacology
Synaptic Transmission - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A very important element controlling serotonin (5-HT) release throughout the brain is the 5-HT1A autoreceptor present on the soma and dendrites of 5-HT neurons since it exerts a negative feedback influence on their firing activity. This 5-HT1A autoreceptor receives an increased activation by endogenous 5-HT at the beginning of a treatment with a selective 5-HT reuptake inhibitor (SSRI) and, consequently, a decreased 5-HT neuronal firing activity is obtained. As the SSRI treatment is prolonged, the 5-HT1A autoreceptor desensitizes and firing activity is restored in the presence of the SSRI. That this adaptive change underlies, at least in part, the delayed therapeutic effect of SSRI in major depression is supported by the acceleration of the antidepressant response by the concomitant administration of the 5-HT1A autoreceptor antagonist pindolol with SSRIs.
ISSN:0077-8923
1749-6632
DOI:10.1111/j.1749-6632.1998.tb10192.x